
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Olverembatinib
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Recipient : Ascentage Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
Details : Olverembatinib is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hepatic Impairment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 15, 2025
Lead Product(s) : Olverembatinib
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Recipient : Ascentage Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
